Home » Newsletters » BioWorld Science

BioWorld Science

March 24, 2015

View Archived Issues

Genmab buys anti-DR5 antibodies and IP from iDD Biotech

Selexipag shows efficacy for the treatment of PAH

Stevia and BioViva collaborate on genetic therapies for diabetes and obesity

Vect-Horus discloses neurotensin analogue for therapeutic hypothermia induction

Janssen patents mGluR2 positive allosteric modulators

Bristol-Myers Squibb describes RORgamma modulators

Biogen: new identity for Biogen Idec

Artery Therapeutics presents data on ABCA1 agonist peptide CS-6253

EAU Madrid: Long-term results from the everolimus EXIST-2 trial

High clinical efficacy of ranpirnase demonstrated against HPV infection

Masitinib receives FDA orphan drug designation for amyotrophic lateral sclerosis

Gilead Sciences begins phase I study of GS-5829

Celdara Medical begins phase I trial of chimeric-antigen receptor T cells

Stempeucel receives EMA advanced therapy medicinal product classification

Prozymex patents DPP-I inhibitors

Hayashikane Sangyo develops blood-vessel improving agents

Scancell's SCIB-2 DNA vaccine synergizes with immune checkpoint inhibitors against tumor cells

Orphan Technologies enzyme replacement therapy receives U.S. orphan designation for homocystinuria

University of Copenhagen's placental malaria vaccine ready for phase I studies

World Tuberculosis Day: a reminder about the ongoing epidemic

Medigene initiates first company-sponsored study of DC vaccine for AML

Takeda licenses rights to ImmunoGen's antibody-drug conjugate technology

Cerulean's phase Ib/II trial of CRLX-101 and bevacizumab in RCC meets primary endpoint

Vertex reports on phase II trial of VX-661 and ivacaftor in F508del-homozygous CF

First proof-of-concept for 64Cu-DOTA-AE-105 in bladder cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...